{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T23:25:29Z","timestamp":1781565929149,"version":"3.54.5"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Growing evidence shows the effects of psychotropic drugs on the evolution of dementia. Until now, only a few studies have evaluated the cost-effectiveness of psychotropic drugs in institutionalized dementia patients. This study aims to assess the cost-utility of intervention performed in the metropolitan area of Barcelona (Spain) (MN) based on consensus between specialized caregivers involved in the management of dementia patients for optimizing and potentially reducing the prescription of inappropriate psychotropic drugs in this population. This analysis was conducted using the Monitoring and Assessment Framework for the European Innovation Partnership on Active and Healthy Ageing (MAFEIP) tool.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The MAFEIP tool builds up from a variety of surrogate endpoints commonly used across different studies in order to estimate health and economic outcomes in terms of incremental changes in quality adjusted life years (QALYs), as well as health and social care utilization. Cost estimates are based on scientific literature and expert opinion; they are direct costs and include medical visits, hospital care, medical tests and exams and drugs administered, among other concepts. The healthcare costs of patients using the intervention were calculated by means of a medication review that compared patients\u2019 drug-related costs before, during and after the use of the intervention conducted in MN between 2012 and 2014. The cost-utility analysis was performed from the perspective of a health care system with a time horizon of 12\u2009months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The tool calculated the incremental cost-effectiveness ratio (ICER) of the intervention, revealing it to be dominant, or rather, better (more effective) and cheaper than the current (standard) care. The ICER of the intervention was in the lower right quadrant, making it an intervention that is always accepted even with the lowest given Willingness to Pay (WTP) threshold value (\u20ac15,000).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The results of this study show that the intervention was dominant, or rather, better (more effective) and cheaper than the current (standard) care. This dominant intervention is therefore recommended to interested investors for systematic application.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12877-021-02287-7","type":"journal-article","created":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T13:02:53Z","timestamp":1621688573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cost-utility analysis of a consensus and evidence-based medication review to optimize and potentially reduce psychotropic drug prescription in institutionalized dementia patients"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3649-5167","authenticated-orcid":false,"given":"Mireia","family":"Massot Mesquida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7602-3792","authenticated-orcid":false,"given":"Frans","family":"Folkvord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9929-4496","authenticated-orcid":false,"given":"Gemma","family":"Seda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5361-7678","authenticated-orcid":false,"given":"Francisco","family":"Lupi\u00e1\u00f1ez-Villanueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9865-7427","authenticated-orcid":false,"given":"Pere","family":"Tor\u00e1n Monserrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,22]]},"reference":[{"issue":"February","key":"2287_CR1","first-page":"1","volume":"86","author":"Scottish Intercollegiate Guideline Network","year":"2006","unstructured":"Scottish Intercollegiate Guideline Network. Management of patients with dementia: A national clinical guideline. Guidel. 2006;86(February):1\u201355.","journal-title":"Guidel"},{"issue":"4","key":"2287_CR2","doi-asserted-by":"publisher","first-page":"0587","DOI":"10.1371\/journal.pmed.0050076","volume":"5","author":"C Ballard","year":"2008","unstructured":"Ballard C, Lana MM, Theodoulou M, Douglas S, McShane R, Jacoby R, et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Med. 2008;5(4):0587\u201399.","journal-title":"PLoS Med"},{"issue":"nov03 1","key":"2287_CR3","doi-asserted-by":"publisher","first-page":"g6420","DOI":"10.1136\/bmj.g6420","volume":"349","author":"A Corbett","year":"2014","unstructured":"Corbett A, Burns A, Ballard C. Don\u2019t use antipsychotics routinely to treat agitation and aggression in people with dementia. BMJ. 2014;349(nov03 1):g6420.","journal-title":"BMJ"},{"issue":"5","key":"2287_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/2040622316658463","volume":"7","author":"RR Tampi","year":"2016","unstructured":"Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016;7(5):229\u201345. https:\/\/doi.org\/10.1177\/2040622316658463.","journal-title":"Ther Adv Chronic Dis"},{"issue":"sep27 4","key":"2287_CR5","doi-asserted-by":"publisher","first-page":"e6231","DOI":"10.1136\/bmj.e6231","volume":"345","author":"S Billioti de Gage","year":"2012","unstructured":"Billioti de Gage S, Begaud B, Bazin F, Verdoux H, Dartigues J-F, Peres K, et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ. 2012;345(sep27 4):e6231.","journal-title":"BMJ"},{"issue":"7819","key":"2287_CR6","first-page":"1","volume":"343","author":"C Coupland","year":"2011","unstructured":"Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ. 2011;343(7819):1\u201315.","journal-title":"BMJ."},{"issue":"2","key":"2287_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.regg.2009.10.002","volume":"45","author":"J G\u00f3mez-Pav\u00f3n","year":"2010","unstructured":"G\u00f3mez-Pav\u00f3n J, Gonz\u00e1lez Garc\u00eda P, Franc\u00e9s Rom\u00e1n I, Vid\u00e1n Astiz M, Guti\u00e9rrez Rodr\u00edguez J, Jim\u00e9nez D\u00edaz G, et al. Recomendaciones en la prevenci\u00f3n de reacciones adversas a medicamentos en personas mayores con demencia. Rev Esp Geriatr Gerontol. 2010;45(2):89\u201396. https:\/\/doi.org\/10.1016\/j.regg.2009.10.002.","journal-title":"Rev Esp Geriatr Gerontol"},{"key":"2287_CR8","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1111\/bcp.14101","volume":"85","author":"SWH Lee","year":"2019","unstructured":"Lee SWH, Mak VSL, Tang YW. Pharmacist services in nursing homes: A systematic review and meta-analysis. Br J Clin Pharmacol. 2019;85:2668\u201388 Blackwell Publishing Ltd.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"2287_CR9","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1007\/s11096-018-0650-8","volume":"40","author":"A Al-Hashar","year":"2018","unstructured":"Al-Hashar A, Al-Zakwani I, Eriksson T, Sarakbi A, Al-Zadjali B, Al Mubaihsi S, et al. Impact of medication reconciliation and review and counselling, on adverse drug events and healthcare resource use. Int J Clin Pharm. 2018;40(5):1154\u201364. https:\/\/doi.org\/10.1007\/s11096-018-0650-8.","journal-title":"Int J Clin Pharm"},{"key":"2287_CR10","doi-asserted-by":"publisher","unstructured":"Alldred DP, Kennedy M-C, Hughes C, Chen TF, Miller P. Interventions to optimise prescribing for older people in care homes. Cochrane Database Syst Rev. 2016. https:\/\/doi.org\/10.1002\/14651858.CD009095 Alldred DP, editor.","DOI":"10.1002\/14651858.CD009095"},{"key":"2287_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/14737167.2017.1370376","volume":"17","author":"SS Hasan","year":"2017","unstructured":"Hasan SS, Thiruchelvam K, Kow CS, Ghori MU, Babar ZUD. Economic evaluation of pharmacist-led medication reviews in residential aged care facilities. Expert Rev Pharmacoecon Outcomes Res. 2017;17:431\u20139 Taylor and Francis Ltd.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"2287_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s40273-015-0270-2","volume":"33","author":"F J\u00f3dar-S\u00e1nchez","year":"2015","unstructured":"J\u00f3dar-S\u00e1nchez F, Malet-Larrea A, Mart\u00edn JJ, Garc\u00eda-Moch\u00f3n L, L\u00f3pez del Amo MP, Mart\u00ednez-Mart\u00ednez F, et al. Cost-utility analysis of a medication review with follow-up Service for Older Adults with Polypharmacy in community pharmacies in Spain: the conSIGUE program. Pharmacoeconomics. 2015;33(6):599\u2013610. https:\/\/doi.org\/10.1007\/s40273-015-0270-2.","journal-title":"Pharmacoeconomics."},{"issue":"9","key":"2287_CR13","doi-asserted-by":"publisher","first-page":"493","DOI":"10.11622\/smedj.2015133","volume":"56","author":"HS Chia","year":"2015","unstructured":"Chia HS, Ho JAH, Lim BD. Pharmacist review and its impact on Singapore nursing homes. Singap Med J. 2015 Sep 1;56(9):493\u2013501. https:\/\/doi.org\/10.11622\/smedj.2015133.","journal-title":"Singap Med J"},{"issue":"4","key":"2287_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/fampra\/cmx007","volume":"34","author":"F Willeboordse","year":"2017","unstructured":"Willeboordse F, Schellevis FG, Chau SH, Hugtenburg JG, Elders PJM. The effectiveness of optimised clinical medication reviews for geriatric patients: Opti- med a cluster randomised controlled trial. Fam Pract. 2017;34(4):437\u201345. https:\/\/doi.org\/10.1093\/fampra\/cmx007.","journal-title":"Fam Pract"},{"key":"2287_CR15","doi-asserted-by":"publisher","unstructured":"Rankin A, Cadogan CA, Patterson SM, Kerse N, Cardwell CR, Bradley MC, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2018. https:\/\/doi.org\/10.1002\/14651858.CD008165 Patterson SM, editor.","DOI":"10.1002\/14651858.CD008165"},{"key":"2287_CR16","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s40273-019-00814-4","volume":"37","author":"DM Dawoud","year":"2019","unstructured":"Dawoud DM, Haines A, Wonderling D, Ashe J, Hill J, Varia M, et al. Cost effectiveness of advanced pharmacy services provided in the community and primary care settings: a systematic review. Pharmacoeconomics. 2019;37:1241\u201360 Springer International Publishing.","journal-title":"Pharmacoeconomics"},{"key":"2287_CR17","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.3390\/ijerph16162955","volume":"16","author":"A Kwak","year":"2019","unstructured":"Kwak A, Moon YJ, Song YK, Yun HY, Kim K. Economic impact of pharmacist-participated medication management for elderly patients in nursing homes: a systematic review. Int J Environ Res Public Health. 2019;16:2955 MDPI AG.","journal-title":"Int J Environ Res Public Health"},{"issue":"7544","key":"2287_CR18","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1136\/bmj.38782.575868.7C","volume":"332","author":"J Fossey","year":"2006","unstructured":"Fossey J, Ballard C, Juszczak E, James I, Alder N, Jacoby R, et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. Br Med J. 2006;332(7544):756\u20138. https:\/\/doi.org\/10.1136\/bmj.38782.575868.7C.","journal-title":"Br Med J"},{"issue":"3","key":"2287_CR19","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1093\/ageing\/afy001","volume":"47","author":"K Van Der Spek","year":"2018","unstructured":"Van Der Spek K, Koopmans RTCM, Smalbrugge M, Nelissen-Vrancken MHJMG, Wetzels RB, Smeets CHW, et al. The effect of biannual medication reviews on the appropriateness of psychotropic drug use for neuropsychiatric symptoms in patients with dementia: a randomised controlled trial. Age Ageing. 2018;47(3):430\u20137. https:\/\/doi.org\/10.1093\/ageing\/afy001.","journal-title":"Age Ageing"},{"issue":"1","key":"2287_CR20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1532-5415.2009.02617.x","volume":"58","author":"SM Patterson","year":"2010","unstructured":"Patterson SM, Hughes CM, Crealey G, Cardwell C, Lapane KL. An evaluation of an adapted U.S. model of pharmaceutical care to improve psychoactive prescribing for nursing home residents in Northern Ireland (Fleetwood Northern Ireland study). J Am Geriatr Soc. 2010;58(1):44\u201353. https:\/\/doi.org\/10.1111\/j.1532-5415.2009.02617.x.","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"2287_CR21","doi-asserted-by":"publisher","first-page":"398","DOI":"10.5694\/mja17.00857","volume":"208","author":"JL Westbury","year":"2018","unstructured":"Westbury JL, Gee P, Ling T, Brown DT, Franks KH, Bindoff I, et al. RedUSe: reducing antipsychotic and benzodiazepine prescribing in residential aged care facilities. Med J Aust. 2018;208(9):398\u2013403. https:\/\/doi.org\/10.5694\/mja17.00857.","journal-title":"Med J Aust"},{"issue":"1","key":"2287_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12913-020-5014-0","volume":"20","author":"ID Maidment","year":"2020","unstructured":"Maidment ID, Barton G, Campbell N, Shaw R, Seare N, Fox C, et al. MEDREV (pharmacy-health psychology intervention in people living with dementia with behaviour that challenges): the feasibility of measuring clinical outcomes and costs of the intervention. BMC Health Serv Res. 2020;20(1):1\u20139.","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"2287_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pmed.1002500","volume":"15","author":"C Ballard","year":"2018","unstructured":"Ballard C, Corbett A, Orrell M, Williams G, Moniz-Cook E, Romeo R, et al. Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: a cluster-randomised controlled trial. PLoS Med. 2018;15(2):1\u201318.","journal-title":"PLoS Med"},{"issue":"10","key":"2287_CR24","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1002\/gps.4572","volume":"32","author":"C Ballard","year":"2017","unstructured":"Ballard C, Orrell M, Sun Y, Moniz-Cook E, Stafford J, Whitaker R, et al. Impact of antipsychotic review and non-pharmacological intervention on health-related quality of life in people with dementia living in care homes: WHELD\u2014a factorial cluster randomised controlled trial. Int J Geriatr Psychiatry. 2017;32(10):1094\u2013103. https:\/\/doi.org\/10.1002\/gps.4572.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"3","key":"2287_CR25","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/ageing\/afz016","volume":"48","author":"C Richter","year":"2019","unstructured":"Richter C, Berg A, Langner H, Meyer G, K\u00f6pke S, Balzer K, et al. Effect of person-centred care on antipsychotic drug use in nursing homes (EPCentCare): a cluster-randomised controlled trial. Age Ageing. 2019;48(3):419\u201325. https:\/\/doi.org\/10.1093\/ageing\/afz016.","journal-title":"Age Ageing"},{"issue":"1","key":"2287_CR26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s40266-017-0513-3","volume":"35","author":"SL Harrison","year":"2018","unstructured":"Harrison SL, Kouladjian O\u2019Donnell L, Bradley CE, Milte R, Dyer SM, Gnanamanickam ES, et al. Associations between the drug burden index, potentially inappropriate medications and quality of life in residential aged care. Drugs Aging. 2018;35(1):83\u201391. https:\/\/doi.org\/10.1007\/s40266-017-0513-3.","journal-title":"Drugs Aging"},{"key":"2287_CR27","doi-asserted-by":"publisher","unstructured":"Van Leeuwen E, Petrovic M, van Driel ML, De Sutter AI, Vander Stichele R, Declercq T, et al. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2018. https:\/\/doi.org\/10.1002\/14651858.CD007726.pub3.","DOI":"10.1002\/14651858.CD007726.pub3"},{"issue":"3","key":"2287_CR28","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1176\/appi.ajp.2015.15010130","volume":"173","author":"C Ballard","year":"2016","unstructured":"Ballard C, Orrell M, Zhong SY, Moniz-Cook E, Stafford J, Whittaker R, et al. Impact of antipsychotic review and nonpharmacological interventionon antipsychotic use, neuropsychiatric symptoms, and mortality in people with dementia living in nursing homes: a factorial cluster-randomized controlled trial by the well-being and health. Am J Psychiatry. 2016;173(3):252\u201362. https:\/\/doi.org\/10.1176\/appi.ajp.2015.15010130.","journal-title":"Am J Psychiatry"},{"key":"2287_CR29","volume-title":"Monitoring and assessment framework for the European innovation partnership on active and healthy ageing (MAFEIP). Second update of the process indicators","author":"F Abadie","year":"2014","unstructured":"Abadie F, Boehler C, Lluch M, Sabes-Figuera R, Zamora B. Monitoring and assessment framework for the European innovation partnership on active and healthy ageing (MAFEIP). Second update of the process indicators; 2014."},{"issue":"3","key":"2287_CR30","first-page":"1","volume":"15","author":"CE Boehler","year":"2015","unstructured":"Boehler CE, De Graaf G, Steuten L, Yang Y, Abadie F. Development of a web-based tool for the assessment of health and economic outcomes of the European innovation partnership on active and healthy ageing (EIP on AHA). BMC Med Inform Decis Mak. 2015;15(3):1\u201310.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"1","key":"2287_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12877-018-1015-9","volume":"19","author":"M Massot Mesquida","year":"2019","unstructured":"Massot Mesquida M, Tristany Casas M, Franzi Sis\u00f3 A, Garc\u00eda Mu\u00f1oz I, Hern\u00e1ndez Vian \u00d3, Tor\u00e1n MP. Consensus and evidence-based medication review to optimize and potentially reduce psychotropic drug prescription in institutionalized dementia patients. BMC Geriatr. 2019;19(1):1\u20139.","journal-title":"BMC Geriatr"},{"key":"2287_CR32","unstructured":"WHO. No Title [Internet]. 2020. Available from: https:\/\/www.whocc.no\/atc_ddd_index\/. Accesed May 2021."},{"key":"2287_CR33","volume-title":"MAFEIP User Guide","author":"S Birov","year":"2017","unstructured":"Birov, Strahil, Christianne Lavin, Veli Stroetmann, Ruth Vilar FL-V. MAFEIP User Guide. 2017. Available from: https:\/\/tool.mafeip.eu\/assets\/files\/MAFEIP_User_Guide_v2_Website.pdf. Cited 2020 Nov 24"},{"key":"2287_CR34","unstructured":"Barcelona: Oblikue. Base de datos de costes sanitarios espa\u00f1oles: eSalud. Available from: http:\/\/esalud.oblikue.com\/. Accesed May 2021."},{"issue":"12","key":"2287_CR35","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1212\/01.wnl.0000249311.80411.93","volume":"67","author":"J Lopez-Bastida","year":"2006","unstructured":"Lopez-Bastida J, Serrano-Aguilar P, Perestelo-Perez L, Oliva-Moreno J. Social-economic costs and quality of life of Alzheimer disease in the Canary Islands, Spain. Neurology. 2006;67(12):2186\u201391. https:\/\/doi.org\/10.1212\/01.wnl.0000249311.80411.93.","journal-title":"Neurology"},{"key":"2287_CR36","volume-title":"Health-Related Quality of Life (HRQOL)","author":"CDC. Centers for Disease Control and Prevention","year":"2020","unstructured":"CDC. Centers for Disease Control and Prevention. Health-Related Quality of Life (HRQOL). 2020. Available from: https:\/\/www.cdc.gov\/hrqol\/index.htm"},{"issue":"5\u20136","key":"2287_CR37","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1159\/000084556","volume":"19","author":"A Sicras","year":"2005","unstructured":"Sicras A, Rejas J, Arco S, Flores E, Ortega G, Esparcia A, et al. Prevalence, resource utilization and costs of vascular dementia compared to Alzheimer\u2019s dementia in a population setting. Dement Geriatr Cogn Disord. 2005;19(5\u20136):305\u201315. https:\/\/doi.org\/10.1159\/000084556.","journal-title":"Dement Geriatr Cogn Disord"},{"issue":"8","key":"2287_CR38","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/gps.1349","volume":"20","author":"M Gobert","year":"2005","unstructured":"Gobert M, D\u2019hoore W. Prevalence of psychotropic drug use in nursing homes for the aged in Quebec and in the French-speaking area of Switzerland. Int J Geriatr Psychiatry. 2005;20(8):712\u201321. https:\/\/doi.org\/10.1002\/gps.1349.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"2287_CR39","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/2050-6511-14-56","volume":"14","author":"M Gustafsson","year":"2013","unstructured":"Gustafsson M, Karlsson S, Gustafson Y, L\u00f6vheim H. Psychotropic drug use among people with dementia--a six-month follow-up study. BMC Pharmacol Toxicol. 2013;14(1):56. https:\/\/doi.org\/10.1186\/2050-6511-14-56.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"1","key":"2287_CR40","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/hup.1160","volume":"26","author":"M Azermai","year":"2011","unstructured":"Azermai M, Elseviers M, Petrovic M, Van Bortel L, Vander SR. Geriatric drug utilisation of psychotropics in Belgian nursing homes. Hum Psychopharmacol. 2011;26(1):12\u201320. https:\/\/doi.org\/10.1002\/hup.1160.","journal-title":"Hum Psychopharmacol"},{"issue":"3","key":"2287_CR41","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/ageing\/afz016","volume":"48","author":"C Richter","year":"2019","unstructured":"Richter C, Berg A, Langner H, Meyer G, K\u00f6pke S, Balzer K, et al. Effect of person-centred care on antipsychotic drug use in nursing homes (EPCentCare): a cluster-randomised controlled trial. Age Ageing. 2019;48(3):419\u201325. https:\/\/doi.org\/10.1093\/ageing\/afz016.","journal-title":"Age Ageing"},{"issue":"1","key":"2287_CR42","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12913-020-5014-0","volume":"20","author":"ID Maidment","year":"2020","unstructured":"Maidment ID, Barton G, Campbell N, Shaw R, Seare N, Fox C, et al. MEDREV (pharmacy-health psychology intervention in people living with dementia with behaviour that challenges): the feasibility of measuring clinical outcomes and costs of the intervention. BMC Health Serv Res. 2020;20(1):157.","journal-title":"BMC Health Serv Res"},{"issue":"June","key":"2287_CR43","first-page":"148","volume":"4788","author":"M Massot","year":"2016","unstructured":"Massot M, Tristany M, Franzi A, Garcia I. Reducing the number of antidepressants, antipsychotics and benzodiazepines in nursing home residents with dementia [Poster]. Int Perspect Prim Care Res. 2016;4788(June):148.","journal-title":"Int Perspect Prim Care Res"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-021-02287-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-021-02287-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-021-02287-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T13:06:33Z","timestamp":1621688793000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgeriatr.biomedcentral.com\/articles\/10.1186\/s12877-021-02287-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,22]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2287"],"URL":"https:\/\/doi.org\/10.1186\/s12877-021-02287-7","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,22]]},"assertion":[{"value":"19 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics and Clinical Research Committee of the Jordi Gol Primary Care Research Institute (IDIAP, <i>Institut d\u2019Investigaci\u00f3 en Atenci\u00f3 Prim\u00e0ria Jordi Gol<\/i>) of the Catalan Health Institute (ICS, <i>Institut Catal\u00e0 de la Salut,<\/i> Code: P15\/120). This paper shows the modeling and economic evaluation of the data from the previous clinical study [] and has been carried out following the guidelines and recommendations of good practice in research (). The Jordi Gol IDIAP constitutes the ethics committee for all primary care activity within the ICS. .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no conflicts of interest related to this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"327"}}